The US Patent Trial and Appeal Board (PTAB) has instituted Samsung Bioepis’ inter partes review (IPR) petition challenging Regeneron’s Eylea® (aflibercept) patent no. 10,464,992 in IPR proceeding IPR2023-01312. The patent claims formulations of aflibercept suitable for intravitreal injection. Samsung Bioepis also successfully filed a Motion for Joinder requesting to join the proceeding with IPR2023-00462, in which PTAB instituted Celltrion’s IPR against the ‘992 patent.
On 18 August 2023 Samsung Bioepis filed an IPR petition against ‘992 and sought joinder with the Celltrion IPR filed against the same Regeneron patent on 17 January 2023.